metaLead Therapeutics develops peptide-based treatments that selectively capture and detoxify non-essential toxic metals, such as lead, while preserving essential metals in the body. Their approach addresses the limitations of current therapies for metal poisoning, offering increased efficacy and reduced side effects through stable, orally available formulations.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for metal poisoning and dysregulation often lack selectivity, leading to the depletion of essential metals alongside the targeted toxins, resulting in significant side effects and limited efficacy. Existing therapies for conditions like lead poisoning and Wilson's disease struggle to achieve safe threshold levels and may have limited applicability for a large percentage of diagnosed patients.
Solution
metaLead Therapeutics is developing a new class of peptide-based therapeutics designed to selectively capture and detoxify specific toxic metals, such as lead and mercury, or to address the misregulation of essential metals like copper in Wilson's disease. Their approach utilizes modified peptides engineered for increased efficacy in metal capture and expulsion from the body, as demonstrated in preclinical studies. These candidates exhibit high selectivity, minimizing off-target effects and preserving essential metals, thereby reducing the side effects associated with current standard-of-care treatments. metaLead's formulations are designed to be stable and orally available, offering a more patient-friendly administration route.
Target Audience
The primary target audience includes patients suffering from metal poisoning (e.g., lead toxicity) and genetic disorders causing metal dysregulation (e.g., Wilson's disease), as well as the healthcare providers who treat them.
Features
- Tailored peptides designed to selectively bind and remove specific toxic metals or address metal dysregulation.
- Preclinical data demonstrating increased efficacy in expelling target metals from blood and organs compared to standard treatments.
- High selectivity to minimize off-target effects and preserve essential metals.
- Stable, orally available formulations for improved patient compliance.
- Potential application in treating both non-essential toxic metal accumulation (e.g., lead poisoning) and essential metal misregulation (e.g., Wilson's disease).